

David D Berg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2570089/publications.pdf>

Version: 2024-02-01

52
papers

1,906
citations

304743

22
h-index

265206

42
g-index

56
all docs

56
docs citations

56
times ranked

2629
citing authors

#	ARTICLE	IF	CITATIONS
1	Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. <i>Circulation</i> , 2022, 145, 158-169.	1.6	18
2	End-of-life care in the cardiac intensive care unit: a contemporary view from the Critical Care Cardiology Trials Network (CCCTN) Registry. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, 11, 190-197.	1.0	11
3	Epidemiology of Acute Heart Failure in Critically Ill Patients With COVID-19: An Analysis From the Critical Care Cardiology Trials Network. <i>Journal of Cardiac Failure</i> , 2022, 28, 675-681.	1.7	8
4	Patients With Acute Coronary Syndromes Admitted to Contemporary Cardiac Intensive Care Units: Insights From the CCCTN Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, .	2.2	5
5	Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 675-681.	2.1	9
6	Biomarkers for Risk Assessment in Atrial Fibrillation. <i>Clinical Chemistry</i> , 2021, 67, 87-95.	3.2	16
7	Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e007034.	3.9	27
8	Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , 2021, 42, 1698-1706.	2.2	27
9	Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2 ^Â Pâ€™TIMI 50. <i>Journal of the American Heart Association</i> , 2021, 10, e018673.	3.7	7
10	The Range of Cardiogenic Shock Survival by Clinical Stage: Data From the Critical Care Cardiology Trials Network Registry. <i>Critical Care Medicine</i> , 2021, 49, 1293-1302.	0.9	41
11	Epidemiology and causes of cardiogenic shock. <i>Current Opinion in Critical Care</i> , 2021, 27, 401-408.	3.2	30
12	Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 499.	6.1	120
13	A Targeted Proteomic Approach Identifies Novel Biomarkers of Arterial Thromboembolic Risk in ENGAGE AF-TIMI 48. <i>Journal of the American College of Cardiology</i> , 2021, 78, 634-636.	2.8	1
14	Management and Outcomes of Cardiogenic Shock in Cardiac ICUs With Versus Without Shock Teams. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1309-1317.	2.8	91
15	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. <i>Diabetes Care</i> , 2021, 44, 2573-2581.	8.6	13
16	Improving prediction of anticoagulant-related major bleeding in atrial fibrillation: The search for new biomarkers. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2674-2676.	3.8	1
17	De Novo vs Acute-on-Chronic Presentations of Heart Failure-Related Cardiogenic Shock: Insights from the Critical Care Cardiology Trials Network Registry. <i>Journal of Cardiac Failure</i> , 2021, 27, 1073-1081.	1.7	37
18	Interpreting Absolute and Relative Risk Reduction in the Context of Recent Cardiovascular Outcome Trials in Patients with Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2021, 21, 45.	4.2	3

#	ARTICLE	IF	CITATIONS
19	Epidemiology of Cardiogenic Shock in Hospitalized Adults With COVID-19: A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry. <i>Circulation: Heart Failure</i> , 2021, 14, CIRCHEARTFAILURE121008477.	3.9	12
20	Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. <i>JACC: Heart Failure</i> , 2020, 8, 834-843.	4.1	19
21	Reply to Blaize et al.: COVID-19–related Respiratory Failure and Lymphopenia Do Not Seem Associated with Pneumocystosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1736-1737.	5.6	5
22	A Case of COVID-19 and <i>Pneumocystis jirovecii</i> Coinfection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 136-138.	5.6	68
23	Use of Temporary Mechanical Circulatory Support for Management of Cardiogenic Shock Before and After the United Network for Organ Sharing Donor Heart Allocation System Changes. <i>JAMA Cardiology</i> , 2020, 5, 703.	6.1	93
24	Cardiopulmonary Resuscitation During the COVID-19 Pandemic. <i>Circulation</i> , 2020, 141, 1833-1835.	1.6	61
25	In Reply to Dyster and Penner. <i>Academic Medicine</i> , 2020, 95, 1626-1627.	1.6	0
26	Editor’s Choice—Prospective registry of cardiac critical illness in a modern tertiary care Cardiac Intensive Care Unit. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 755-761.	1.0	24
27	Clinical Practice Patterns in Temporary Mechanical Circulatory Support for Shock in the Critical Care Cardiology Trials Network (CCCTN) Registry. <i>Circulation: Heart Failure</i> , 2019, 12, e006635.	3.9	58
28	Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center. <i>Circulation: Heart Failure</i> , 2019, 12, e006214.	3.9	100
29	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 140, 1569-1577.	1.6	94
30	EPIDEMIOLOGY OF SHOCK IN CONTEMPORARY CARDIAC INTENSIVE CARE UNITS: DATA FROM THE CRITICAL CARE CARDIOLOGY TRIALS NETWORK (CCCTN) REGISTRY. <i>Journal of the American College of Cardiology</i> , 2019, 73, 666.	2.8	2
31	Epidemiology of Shock in Contemporary Cardiac Intensive Care Units. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005618.	2.2	232
32	Key components of a community response to out-of-hospital cardiac arrest. <i>Nature Reviews Cardiology</i> , 2019, 16, 407-416.	13.7	13
33	CONTRIBUTORS TO RESPIRATORY FAILURE AND OUTCOMES IN THE CARDIAC INTENSIVE CARE UNIT. <i>Journal of the American College of Cardiology</i> , 2019, 73, 216.	2.8	0
34	A Dangerous Detour. <i>New England Journal of Medicine</i> , 2019, 380, 1360-1365.	27.0	1
35	Fostering Meaning in Residency to Curb the Epidemic of Resident Burnout: Recommendations From Four Chief Medical Residents. <i>Academic Medicine</i> , 2019, 94, 1675-1678.	1.6	22
36	Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. <i>Circulation</i> , 2019, 139, 760-771.	1.6	99

#	ARTICLE	IF	CITATIONS
37	A Dangerous Detour. <i>New England Journal of Medicine</i> , 2019, 380, e18.	27.0	1
38	Cardiac Implantable Electronic Devices in Patients With Left Ventricular Assist Systems. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1483-1493.	2.8	26
39	Modes and timing of death in 66%252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. <i>European Heart Journal</i> , 2018, 39, 3810-3820.	2.2	28
40	Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia. <i>European Journal of Heart Failure</i> , 2017, 19, 682-685.	7.1	39
41	PLATYPNEA-ORTHODEOXIA IN A LEUKEMIA PATIENT WITH A TRICUSPID VALVE MASS. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2226.	2.8	0
42	Management of Cardiac Tamponade. , 2017, , 129-134.		0
43	Deep T-Wave Inversions After Pacemaker Adjustment. <i>JAMA Internal Medicine</i> , 2016, 176, 839.	5.1	0
44	Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2P-TIMI 50). <i>American Journal of Cardiology</i> , 2016, 117, 1055-1058.	1.6	5
45	Outcomes in patients undergoing percutaneous ventricular assist device implantation for cardiogenic shock. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 108-116.	1.0	14
46	Variability of Individual Platelet Reactivity Over Time in Patients Treated With Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2014, 64, 361-368.	2.8	70
47	173. <i>Critical Care Medicine</i> , 2014, 42, A1402.	0.9	1
48	Novel Biomarkers in Cardiovascular Disease. <i>Cardiology in Review</i> , 2012, 20, 111-117.	1.4	11
49	When Should Rescue Breathing Be Removed From the ABCs of CPR?. <i>Critical Care Clinics</i> , 2012, 28, 155-165.	2.6	4
50	The facts behind niacin. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2011, 5, 227-240.	2.1	20
51	Immediate post-shock chest compressions improve outcome from prolonged ventricular fibrillation. <i>Resuscitation</i> , 2008, 78, 71-76.	3.0	32
52	Interruptions of Chest Compressions During Emergency Medical Systems Resuscitation. <i>Circulation</i> , 2005, 112, 1259-1265.	1.6	286